Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...

The popular weight-loss and diabetes medication tirzepatide is no longer in short supply, the Food and Drug Administration said. Eli Lilly's tirzepatide, sold as Zepbound for weight loss and ...

Doctors and law enforcement are raising concerns about the growing trend of people selling weight loss drugs like Ozempic and ...

Diabetes treatment Mounjaro has been on the health regulator's shortage list since late 2022, while weight-loss drug Zepbound was added in April as demand far outstripped supply. The limited ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

Demand for new weight loss drugs has surged over the past few years. Led by the antiobesity drugs semaglutide (Wegovy) and tirzepatide (Zepbound), these popular medications — more commonly known ...

Mounjaro and Zepbound, could result in unexpected side effects. In India, two other drugs are being used for weight loss: liraglutide, an injectable that has been available for several years ...

Eli Lilly (NYSE:LLY) is reportedly looking to study its popular weight-loss drug Zepbound in people who aren't considered overweight but are still at risk for developing conditions such as diabetes.